Document Detail


Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers.
MedLine Citation:
PMID:  19783713     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The influence of pantoprazole 40 mg twice daily on the bioavailability of a single dose of mycophenolate mofetil 1000 mg or enteric-coated mycophenolate sodium is investigated in healthy volunteers. The plasma concentrations of mycophenolic acid and of the inactive metabolite mycophenolic acid glucuronide are measured by high-performance liquid chromatography. The pharmacokinetic parameters following sole administration are similar for mycophenolate mofetil and enteric-coated mycophenolate sodium except for the time to peak concentration, which is longer in the enteric-coated mycophenolate sodium group. Concomitant treatment with pantoprazole significantly (P < .001) lowers the mycophenolic acid exposure following administration of mycophenolate mofetil. The peak concentrations drop by 57%, and area under the curve decreases from 0 to 12 hours by 27%. In contrast, pantoprazole does not change the pharmacokinetics of enteric-coated mycophenolate sodium. Given that mycophenolic acid exposure correlates with the incidence of biopsy-proven acute rejections in renal transplant recipients, these findings may have clinical implications. Administration of pantoprazole in combination with mycophenolate mofetil could possibly result in an insufficient mycophenolic acid exposure, increasing the risk of treatment failure.
Authors:
Korbinian Rupprecht; Christoph Schmidt; Anne Raspé; Frank Schweda; Maria Shipkova; Wolfgang Fischer; Michael Bucher; Frieder Kees; Lothar Faerber
Related Documents :
23830453 - In situ extractive fermentation for the production of hexanoic acid from galactitol by ...
24530133 - Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid ...
17522303 - Characterization of ligands for fish taste receptors.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  49     ISSN:  1552-4604     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-28     Completed Date:  2009-12-11     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1196-201     Citation Subset:  IM    
Affiliation:
Department of Anesthesiology, University of Regensburg, Regensburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects*,  blood
Anti-Ulcer Agents / adverse effects
Biological Availability
Drug Interactions
Female
Glucuronides / blood
Humans
Immunosuppressive Agents / pharmacokinetics*
Male
Mycophenolic Acid / analogs & derivatives*,  blood,  pharmacokinetics
Tablets, Enteric-Coated / pharmacokinetics
Time Factors
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Glucuronides; 0/Immunosuppressive Agents; 0/Tablets, Enteric-Coated; 0/mycophenolic acid glucuronide; 24280-93-1/Mycophenolic Acid; 9242ECW6R0/mycophenolate mofetil; D8TST4O562/pantoprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of dr...
Next Document:  Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in...